Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/946c0724-0a2a-4f36-ba3b-2515d7faf66b/

PDEX

Pro-Dex Inc
Chart
54.93 USD
Latest Week 2026-07-24
Snapshot 2026-07-26 · 0.6w · Fresh
0.55
OS Score
34.0%
Value
70.0%
Quality
66.0%
Momentum
6/9
F-Score
0.488
QV
Strategy Eligibility
5 of 23 passing
OS Composite
Trending Value
Quality × Value
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
P/E 14.6
VC2 Cheapest
📐
EBITDA/EV
10.6%
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
ROE 27%
📈
Consistent Earners
🌱
GARP
Rev +16%
🔄
Shareholder Yield
💰
High Yield
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
CAQ 0.89
Risk-Adj Momentum
V
Value Analysis
Cheapness relative to fundamentals
34.0%ile
P/E
14.6×
P/S
2.3×
P/B
3.9×
E/P
0.0935
FCF Yield
0.042
EBITDA/EV
0.106
SH Yield
0.016
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
71.00000000
/100 — 1=cheapest
VC2 (Trending Value)
72.00000000
/100
VC3 (Buyback)
72.00000000
/100
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
70.0%ile
ROE
0.266
ROA
0.160
Net Margin
0.161
Op Margin
0.232
GPA
0.277
D/E
0.66
Current
3.67
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.164
Earn Growth
0.281
Stability
0.448
lower=better
Accruals
0.062
lower=better
5yr Consist
No
ROE of 27% is exceptional.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
66.0%ile
6M Return
40.4%
12M Return
11.1%
12-1 Mom
24.4%
Risk-Adj
0.38
Vol 252d
63.6%
Vol 60d
112.0%
↑ Expanding
Max DD 12M
-45.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 24% is very strong — a clear uptrend. Near-term vol (112%) is expanding vs long-term (64%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.55
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
9.4%
Sector Quality %ile
79.8%
P/E z-score
-0.21
P/B z-score
-0.12
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
THC Tenet Healthcare Corporation 97.0% 90.0% 91.0% 81.0%
Factor Interactions
Growth at Reasonable Price
Revenue growing 16% with P/E of 15×. Growth isn't fully priced in.
Volatility Expanding
60-day vol (112%) significantly exceeds 252-day (64%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
58.2% avg (7 factors)
Quality
B
72.6% avg (8 factors)
Momentum
C
58.5% avg (4 factors)
Risk
F
10.7% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.550—0
Value %ile0.340—0
Quality %ile0.700—1
Momentum %ile0.660—0
F-Score6.000—0
Confidence0.929—8
Volatility0.636—8
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
14.61
Earnings Yield (E/P)
0.0935
Price / Sales
2.35
Price / Book
3.88
Price / Cash Flow
23.89
FCF Yield
4.2%
EBITDA / EV
10.6%
Sales Yield (1/P·S)
0.4022
Shareholder Yield
Div + net buyback / mktcap
1.6%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
26.6%
Return on Assets
16.0%
Net Margin
16.1%
Operating Margin
23.2%
Gross Profit / Assets
Novy-Marx GPA
27.7%
Debt / Equity
0.66
Current Ratio
3.67
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.062
External Financing
Net issuance — lower=better
0.039
MomentumPrice trend strength over different horizons
6M Return
40.4%
12M Return
11.1%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
24.4%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.38
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
16.4%
Earnings Growth (YoY)
28.1%
Earnings Stability (CV)
Lower = more stable
0.448
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Buyback Yield
1.6%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
71
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
72
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
72
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity